Leadership Transition at PharmaSGP Holding SE: Peter Gerckens to Succeed Natalie Weigand as CEO

PharmaSGP Holding SE, a prominent German OTC pharmaceutical company, is preparing for a leadership change. Peter Gerckens will succeed Natalie Weigand as Chief Executive Officer on January 1, 2025. After seven years as CEO, Weigand has decided not to renew her contract for personal reasons. Gerckens, who joined PharmaSGP as Chief Commercial Officer in July 2024, is expected to ensure a smooth transition and continue the company's growth trajectory.

The internal succession plan aims for continuity, maintaining Michael Rudolf in his long-standing role as Chief Financial Officer. Weigand will stay with the company in an advisory capacity, supporting future endeavors. Her tenure at PharmaSGP saw significant revenue and earnings milestones, cementing her impact on the company's success.

Peter Gerckens expressed admiration for the achievements under Weigand's leadership and is poised to advance PharmaSGP's mission with the aid of the dedicated team. The Supervisory Board, led by Dr. Clemens Fischer, supports this transition, confident in Gerckens's understanding of the company's business model and growth opportunities.